Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes

Monotherapy with DPP-IV inhibitors, SGLT-2 inhibitors or insulin secretagogues frequently failed to maintain blood glucose in patients with type 2 diabtes. It was critical to determine which was more suitable of acarbose versus metformin plus pioglitazone.

Inclusion Criteria:Willing to participate in this present study;Patients with type 2 diabetes receiving stable monotherapy of DPP-IV inhibitors, SGLT-2 inhibitors or insulin secretagogues for more than 3 months;Screening glycated hemoglobin (HbA1c) between 7.0% and 10.0%;Regular diet and exercise;Body mass index (BMI) ≥ 18.5 kg/m2Exclusion Criteria:Intolerance of metformin, pioglitazone and acarbose;Severe liver disease or elevated transaminases (2.5-fold the upper limit);Renal dysfunction or elevated creatinine (1.3-fold the upper limit);Systemic steroids therapy or other medication influencing cholesterol metabolism in the past 3 months;Infection or stress state in the past 4 weeks;Pregnancy or lactation;Patients otherwise adjudged by the investigator to be inappropriate for inclusion into the study.